Increased number of prostate cancer patients selecting high dose-rate interstitial brachytherapy during the COVID-19 pandemic

Murakami, Naoya; Nakamura, Satoshi; Kashihara, Tairo; Inaba, Koji; Kaneda, Tomoya; Takahashi, Kana; Okuma, Kae; Igaki, Hiroshi; Itami, Jun

doi:10.1016/j.radonc.2020.11.015

Cited by 2 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Muramaki et al reported increased number of prostate cancer patients, selecting high dose-rate interstitial brachytherapy in our department [ 99 ].…”

Section: Resultsmentioning

confidence: 99%

Covid-19 and radiotherapy: a systematic review after 2 years of pandemic

Piras¹,

Venuti

D’Aviero³

et al. 2022

Clin Transl Imaging

View full text Add to dashboard Cite

Introduction Following the Covid-19 pandemic spread, changes in clinical practice were necessary to limit the pandemic diffusion. Also, oncological practice has undergone changes with radiotherapy (RT) treatments playing a key role. Although several experiences have been published, the aim of this review is to summarize the current evidence after 2 years of pandemic to provide useful conclusions for clinicians. Methods A Pubmed/MEDLINE and Embase systematic review was conducted. The search strategy was “Covid AND Radiotherapy” and only original articles in the English language were considered. Results A total of 2.733 papers were obtained using the mentioned search strategy. After the complete selection process, a total of 281 papers were considered eligible for the analysis of the results. Discussion RT has played a key role in Covid-19 pandemic as it has proved more resilient than surgery and chemotherapy. The impact of the accelerated use of hypofractionated RT and telemedicine will make these strategies central also in the post-pandemic period.

show abstract

“…Muramaki et al reported increased number of prostate cancer patients, selecting high dose-rate interstitial brachytherapy in our department [ 99 ].…”

Section: Resultsmentioning

confidence: 99%

Covid-19 and radiotherapy: a systematic review after 2 years of pandemic

Piras¹,

Venuti

D’Aviero³

et al. 2022

Clin Transl Imaging

View full text Add to dashboard Cite

show abstract

Radiotherapy based management during Covid-19 pandemic – A systematic review of presented consensus and guidelines

Siavashpour

Goharpey²,

Mobasheri

2021

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Treatment management of cancer patients in the radiation oncology departments during the current COVID-19 pandemic is challenging. A systematic review of published consensus/guidelines on the role of radiotherapy prioritization, suggested treatment protocols, and set up management was undertaken based on the PRISMA protocol and through PubMed/PMC, Scopus, Google Scholar, Web of Science databases until 01/20/2021. One hundred and sixty-eight publications or regional consensus were included. Summary of recommendations contained: (1) using hypo-fractionated (Hypo-F) regimens for therapeutic/palliative indications, (2) delaying radiotherapy for several weeks or until pandemic over, (3) omitting radiotherapy by replacement of alternative therapies or active surveillance, (4) applying safer patients' setup and preparation protocols, (5) developing telemedicine/telehealth service. To conclude, it is essential to carefully weigh the risk of exposure to COVID-19 infection and the benefit of treating cancer patients during the pandemic. Trying to have a global guideline facing this or any other probable crisis is crucial for health care service.

show abstract

Increased number of prostate cancer patients selecting high dose-rate interstitial brachytherapy during the COVID-19 pandemic

Cited by 2 publications

References 16 publications

Covid-19 and radiotherapy: a systematic review after 2 years of pandemic

Covid-19 and radiotherapy: a systematic review after 2 years of pandemic

Radiotherapy based management during Covid-19 pandemic – A systematic review of presented consensus and guidelines

Contact Info

Product

Resources

About